International life sciences company, GBA Group has acquired a significant stake in pharma services in Bengaluru-based Eureka Analytical Services, one of India‘s fastest-growing testing labs & inspection service providers. Starting with this investment, the GBA Group will continuously seek opportunities for further investment in the pharma testing market in India.
"By entering the Indian market together with such a professional, successful, and dynamically growing company as Eureka, we are creating a win-win situation for both parties. For the GBA Group, there is enormous growth potential in India over the next few years as well as further options for further expansion into the Asian market. This applies above all to the Indian pharmaceutical and medical technology market," explains Steffen Walter, CEO, GBA Group.
In the next 2 years, Eureka plans to increase the number labs in India and overseas. With GBA Group as a shareholder, Eureka aims to expand its presence in the international pharma market by extending its offerings to its international customer network. Eureka will continue to upgrade and scale its testing platforms to grow its footprint in India and key markets overseas and develop its R&D efforts, while simultaneously engaging with customers in the pharmaceutical segment.
"We are proud to now be an official member of the GBA Group and to continue our successful partnership! As partners, we have already been able to successfully promote and utilize each other's expertise in the past. In the future, we will further strengthen our presence in the international market and expand our international customer network with a broader range of services. As part of our strong partnership, we will also accelerate market entry into new business areas and develop the GBA Group network through Eureka in areas such as pharmaceuticals, medical devices, and agrochemicals," said Sanjeev Khatri and Dr. Gouri Satpathy, Eureka Analytical Services.
"By entering the Indian market together with such a professional, successful, and dynamically growing company as Eureka, we are creating a win-win situation for both parties. For the GBA Group, there is enormous growth potential in India over the next few years as well as further options for further expansion into the Asian market. This applies above all to the Indian pharmaceutical and medical technology market," explains Steffen Walter, CEO, GBA Group.
In the next 2 years, Eureka plans to increase the number labs in India and overseas. With GBA Group as a shareholder, Eureka aims to expand its presence in the international pharma market by extending its offerings to its international customer network. Eureka will continue to upgrade and scale its testing platforms to grow its footprint in India and key markets overseas and develop its R&D efforts, while simultaneously engaging with customers in the pharmaceutical segment.
"We are proud to now be an official member of the GBA Group and to continue our successful partnership! As partners, we have already been able to successfully promote and utilize each other's expertise in the past. In the future, we will further strengthen our presence in the international market and expand our international customer network with a broader range of services. As part of our strong partnership, we will also accelerate market entry into new business areas and develop the GBA Group network through Eureka in areas such as pharmaceuticals, medical devices, and agrochemicals," said Sanjeev Khatri and Dr. Gouri Satpathy, Eureka Analytical Services.
